A meteor may have led to the formation of the Grand Canyon, new study says
While many Americans are familiar with the Grand Canyon's beauty and uniqueness, they may not be aware of the story behind its formation.
The Colorado River may have etched the canyon one mile deep, as rocky debris transported in floods did most of the carving, according to the Grand Canyon Conservancy.
But what caused the flooding?
A study published in Geology on Tuesday tied another Arizona landmark, the Meteor Crater, to the formation of the Grand Canyon.
A meteor may have led to the formation of the Grand Canyon, a new study has found (Daniel Slim/AFP via Getty Images)
The study hypothesized the Meteor Crater, which was formed 56,000 years ago, triggered landslides in the Grand Canyon that blocked the Colorado River and formed a paleolake — a lake that has existed in the past— in the canyon.
Geologists have long wondered how and when driftwood found in Stanton's Cave in the Grand Canyon got there, as the mouth of the cave is 150 feet above the river. There are also lake sediments found in the cave.
"It would have required a 10-times bigger flood level than any flood that has happened in the past several thousand years,' one of the study's authors, University of New Mexico Distinguished Professor Emeritus Karl Karlstrom, said in a press release Tuesday.
He continued: 'Or maybe they are very old deposits left as the river carved down, or maybe they floated in from a paleolake caused by a downstream lava dam or landslide dam? We needed to know the age of the cave deposits.'
A study published Tuesday tied the Meteor Crater to the formation of the Grand Canyon (Daniel Slim/AFP via Getty Images)
The study hypothesized the Meteor Crater, which was formed 56,000 years ago, triggered landslides in the Grand Canyon that blocked the Colorado River and formed a paleolake, in other words, a former lake, in the canyon ()
The study found the driftwood to be 56,000 years old, the same geologic age as the asteroid impact and the landslide dam.
Researchers suggested because the landslide appears to have the same age as Meteor Crater, the asteroid impact blast caused the landslide.
The paleolake formed from the landslide, which dammed the Colorado River. Caves, such as Stanton's Cave, were flooded by the paleolake.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
22 minutes ago
- Fox News
Sean Duffy: If We Went To The Moon, We Can Fix Air Traffic Control
U.S. Secretary of Transportation and interim NASA Administrator Sean Duffy joins Fox Across America With Jimmy Failla to shed light on the space agency's fast-track plan to build a nuclear reactor on the moon. 'So the South Pole of the moon has ice. Ice means water, water means life. It also gets a lot of sunlight in the South pole, but you need a more reliable energy source, which is nuclear. I mean, this the final frontier in America, from the pilgrims to the pioneers, like, we have this explorer tenacity within us. And this is the next phase of exploration. It's to the moon, it's to Mars, it's to beyond. And what's important is that if we cede space to whether it's the Russians or the Chinese or to others, you're going to lose on Earth. This is truly the next frontier. And again, we have peaceful intentions. You've seen it's what we do around the world. We love democracy, we love peace, we don't have any ill will. I'm just not so sure what others think, what their intentions are. So I'd like us and our coalition to get there first. And, again, as we come into next year, it's our Artemis program. We have Artemis 2, we have four amazing astronauts that are going out to the Moon, going around and coming back. Artemis 3, which is going to be about a year after that. We're going to land on the moon. We're gonna stay six days. And in the interim, we're working on our rockets, on getting our assets to the moon, so when Artemis 4 and 5 happens, we have the infrastructure there to build out a base on the Moon, which we're gonna learn from there to then get us to the next difficult phase, which is Mars.' Sean Duffy Says How Products Move Is Going To Radically Change Over The Next Decade Secretary Duffy also details the Department of Transportation's ongoing efforts to modernize the nation's air traffic control system. Listen to the podcast to hear the full conversation!
Yahoo
an hour ago
- Yahoo
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents. Revenues increased to $811.085 million, beating the consensus of $774.34 million. Sales jumped 16% on a reported and core revenue basis, including Screening revenue of $628 million and Precision Oncology revenue of $183 margin was 69%, and adjusted gross margin was 72%. In addition, Exact Sciences shared initial results from an internal version of its colorectal cancer (CRC) blood test, showing sensitivities of 73% for CRC and 14% for APL at 90% specificity. Internal testing and evaluation of the assay are ongoing. Outlook Exact Sciences raised its fiscal 2025 sales guidance from $3.07 billion-3.12 billion to $3.13 billion-$3.17 billion versus the consensus of $3.099 billion. The guidance includes a Screening segment sales forecast of $2.44 billion-$2.47 billion, compared to previous guidance of $2.39 billion-$2.43 billion. Precision Oncology sales are expected to be $690 million-$700 million, compared to prior guidance of $680 million-$695 million. The company expects 2025 adjusted EBITDA of $455 million-$475 million, up from previous guidance of $425 million-$455 million. M&A Deal Exact Sciences on Thursday agreed to acquire exclusive rights in the United States to current and future versions of Freenome's blood-based, single-indication colorectal cancer (CRC) screening tests. View more earnings on EXAS Complete findings from the prospective PREEMPT study were recently published in JAMA. Results show Freenome's first version test achieved sensitivities of 81% for CRC and 14% for advanced precancerous lesions (APL) at specificity of 90%. Freenome recently submitted the last module of the premarket application to the FDA. Freenome then plans to submit a supplement to the FDA for its next-generation test once final clinical validation data are available. Analyst Reaction William Blair writes that investors are most focused on acquisition of the exclusive rights to Freenome's current and future blood-based colorectal cancer (CRC) screening tests. The announcement comes as the company's blood CRC test did not meet expectations in the pivotal trial. Analyst Andrew Brackmann notes that shares are trading lower, representing an opportunity to build or add to positions. William Blair notes that the Freenome deal helps the company move faster in making money from these tests, reduces the threat from competitors, and eases investor concerns that blood-based CRC tests could slow down growth in its screening business. It strengthens the company's position as the top player in noninvasive CRC screening. William also expects the numbers to improve later this year and into 2026. William Blair reiterated the Outperform rating. Barclays maintained its Overweight rating but adjusted its price forecast downward from $65 to $55. Similarly, RBC Capital kept its Sector Perform rating for Exact Sciences, reducing its price forecast from $54 to $46. Finally, UBS reiterated its Neutral stance on the company, lowering its price forecast from $61 to $53. Price Action: EXAS stock is trading lower by 12.3% to $41.13 at last check Thursday. Read Next:Photo by Faces Portrait via Shutterstock Latest Ratings for EXAS Date Firm Action From To Feb 2022 Wells Fargo Maintains Equal-Weight Feb 2022 Citigroup Maintains Neutral Feb 2022 Raymond James Maintains Outperform View More Analyst Ratings for EXAS View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? EXACT SCIENCES (EXAS): Free Stock Analysis Report This article Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
an hour ago
- Bloomberg
Eli Lilly's Experimental Weight-Loss Pill Data Disappoints
A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental drug has less success than its injectable counterparts like Zepbound, Wegovy, and Ozempic. (Source: Bloomberg)